The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease

The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease - The effect of prostaglandin I2 analogue on diabetic nephropathy in diabetic patients with peripheral arterial disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010035

Enrollment

Registered

2013-02-19

Start date

2013-02-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

Oral beraprost sodium administration (60 &amp

micro

g) third daily. standard therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age more than 20 years 2) Outpatients 3) Diabetic nephropathy in patients with peripheral arterial disease 4) Serum Creatinine<2.0mg/dl 5) Patients who themselves can voluntarily provide written consent to participate in this study, and can also follow the study protocol

Exclusion criteria

Exclusion criteria: 1) Previous administration of pioglitazone or DPP-4 inhibitor as an oral hypoglycemic drug 2) 8.0% more than fasting HbA1c 3) Patients with proliferative diabetic retinopathy 4) Patients with bleeding tendency 5) Severe hepatopathy/nephropathy or heart disease that may affect the evaluation of drug safety 6) Patients who are deemed to be inappropriate by the investigator or sub-investigators

Design outcomes

Primary

Measure	Time frame
Creatinine, eGFR, cystatin C	—

Countries

Japan

Contacts

Public ContactAyaka Shima

Nippon Medical School Department of Medicine Division of Cardiology

ykubota@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026